The NSAID Family

## Overview

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications globally, taken for pain, fever, and inflammation. They inhibit cyclooxygenase (COX, also called prostaglandin H synthase) enzymes—COX-1 and COX-2—that catalyze the first committed step in prostaglandin and thromboxane biosynthesis from arachidonic acid. The inhibition of prostaglandins underlies both the therapeutic effects (analgesia, anti-inflammation, antipyresis) and the principal adverse effects (GI mucosal injury, renal vasoconstriction, and—for COX-2 selective agents—cardiovascular risk).

## COX Active Site Architecture

Both COX-1 and COX-2 form a hydrophobic channel above the heme prosthetic group, lined by Phe381, Tyr385, Trp387, Phe518, Ser530, and Leu384. Arachidonic acid threads this channel in a "bent" conformation, with its carboxylate head forming an ionic interaction with Arg120 and Tyr355 at the channel entrance and C13 positioned for oxygenation by Tyr385 radical.

NSAIDs bind competitively in this channel, with the acid group anchored to Arg120 and the hydrophobic aryl scaffold occupying the fatty acid tail region. Aspirin uniquely acetylates Ser530, irreversibly blocking the channel. All other NSAIDs are reversible (or slow-tight binding) inhibitors.

## COX-1 vs COX-2 Selectivity

COX-1 and COX-2 differ by a single residue at position 523: COX-2 has Val523, while COX-1 has Ile523. The smaller Val523 in COX-2 opens a secondary side pocket ("time-dependent inhibitor binding site") adjacent to the main channel, accessible to substituents extending perpendicular to the chain axis. All selective COX-2 inhibitors (coxibs) exploit this pocket with a sulfonamide, methylsulfonyl, or equivalent group: celecoxib's 4-sulfonamidophenyl, rofecoxib's 4-methylsulfonylphenyl, etoricoxib's 2-methylpyridyl-methylsulfonyl all extend precisely into the Val523 pocket without fitting the larger Ile523 pocket of COX-1.

## Profen Class: Chiral 2-Arylpropionic Acids

Profens (ibuprofen, naproxen, ketoprofen, flurbiprofen) are 2-arylpropionic acids with a chiral alpha-methyl group. The (S)-enantiomer is active (binds COX channel with correct methyl orientation); the (R)-enantiomer is inactive at COX. Ibuprofen is sold as a racemate but undergoes one-directional (R→S) chiral inversion in vivo, catalyzed by alpha-methylacyl-CoA racemase (AMACR). Naproxen is sold as the pure (S)-(+)-enantiomer; ketoprofen as (S)-enantiomer (dexketoprofen). The methyl group of the profen scaffold forces the aryl ring to occupy the hydrophobic channel in a specific orientation, and the spatial relationship between the methyl, aryl, and carboxylate determines COX isotype preference.

## Coxibs and Cardiovascular Risk

The selective COX-2 inhibitors (coxibs) were designed to reduce GI toxicity by sparing COX-1's protective gastric prostaglandin production. COX-2 is the dominant isoform in endothelial cells producing prostacyclin (PGI2, anti-aggregatory/vasodilatory) and in inflamed tissues. Rofecoxib's cardiovascular signal (increased MI/stroke in APPROVe trial, leading to voluntary withdrawal in 2004) was attributed to the imbalance: COX-2 inhibition reduced endothelial PGI2 without reducing platelet COX-1-derived thromboxane A2, shifting toward a prothrombotic state. Celecoxib, with lower COX-2 selectivity than rofecoxib, has a less pronounced cardiovascular signal. Non-selective NSAIDs partially avoid this imbalance but cause GI mucosal injury and impair platelet function.

## Aspirin: Irreversible Acetylation

Aspirin (acetylsalicylic acid) is the only NSAID that inhibits COX irreversibly. The acetyl group is transferred from aspirin to Ser530 in the COX channel, blocking substrate access permanently. Because platelets lack nuclei and cannot synthesize new COX-1, low-dose aspirin (75–100 mg) irreversibly inhibits platelet thromboxane A2 for the platelet's lifetime (~7–10 days), providing selective antithrombotic effects without fully inhibiting endothelial prostacyclin (endothelial cells synthesize new COX-2). This distinguishes aspirin's antiplatelet mechanism from therapeutic anti-inflammatory NSAIDs.

## Key Takeaways

- Carboxylate-Arg120 ionic interaction is the universal NSAID pharmacophore; positioning the aryl group in the COX channel requires optimal chain length (1-2 carbons)
- COX-2 selectivity exploits the Val523 side pocket; sulfonamide/methylsulfonyl groups fit COX-2 but not COX-1 (Ile523)
- Profen stereocenters: (S)-isomers are active; ibuprofen undergoes chiral inversion in vivo; naproxen is enantiopure (S)
- Selective COX-2 inhibitors reduce GI toxicity but increase cardiovascular risk by sparing platelet COX-1 thromboxane
- Aspirin's irreversible Ser530 acetylation gives selective antiplatelet effects at low doses, distinct from anti-inflammatory NSAIDs